Table 3.

Response and survival of patients according to genotypes

	n	ROS1 positive	ROS1 negative	P
No. of patients evaluated in first line chemotherapy	56	3	53
CR		0 (0.0)	0 (0.0)
PR		1 (33.3)	11 (20.8)
SD		2 (66.7)	25 (47.2)
PD		0 (0.0)	17 (32.1)
ORR		1 (33.3)	11 (20.8)	0.586
PFS, month (95% CI)		7.8 (2.039–13.561)	3.5 (2.686–4.314)	0.200
No. of patients evaluated in any-line TKIs therapy	27	2	25
CR		0 (0.0)	0 (0.0)
PR		0 (0.0)	2 (8.0)
SD		0 (0.0)	10 (40.0)
PD		2 (100.0)	13 (52.0)
ORR		0 (0.0)	2 (8.0)	0.573
PFS, month (95% CI)		0.9	2.5 (1.031–3.969)	0.040
Overall survival, month (95% CI)		12.1 (3.297–20.903)	8.0 (4.720–11.280)	0.687

CI, confidence interval

CR, complete response

ORR, overall response rate

PD, progressive disease

PFS, progression-free survival

PR, partial response

ROS1, c-ros oncogene 1

SD, stable disease

TKIs, tyrosine kinase inhibitors.